Virtual Library

Start Your Search

Claudia Aparecida Rainho

Author of

  • +

    P3.04 - Immunooncology (Not CME Accredited Session) (ID 970)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.04-03 - Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study (ID 13913)

      12:00 - 13:30  |  Author(s): Claudia Aparecida Rainho

      • Abstract
      • Slides


      Blockade of immune checkpoints with monoclonal antibodies has recently emerged as a novel therapy against cancer. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) is a potent immunoregulatory molecule which regulate T- cell activation and proliferation. The most studied +49A/G polymorphism (rs231775) of the CTLA-4 gene has been associated with several autoimmune diseases and cancer.This study aimed to investigate the relationship between +49A/G polymorphism can predict the prognosis of patients with early stage non-small cell lung cancer (NSCLC) after surgical resection in Brazilian population.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Genomic DNA (gDNA) was extracted from fresh-frozen NSCLC tissue using the QIAamp DNA Mini Kit (Qiagen, Valencia, USA) following the manufacturer’s recommendations. The CTLA-4 gene was customized in a amplicon-based assay for targeted resequencing by TruSeq Custom Amplicon v1.5kit (TSCA, Illumina) on an Illumina MiSeq instrument (Illumina, San Diego, CA, USA). SNPs with minor allele frequency (MAF) of 0.05 or higher were included. X2 test was used to assess the association between CTLA-4 49A/G SNP and categorical clinicopathologic parameters. The overall survival (OS) estimates were calculated using the Kaplan-Meier method. p <0.05 was considered as statistically significant.

      4c3880bb027f159e801041b1021e88e8 Result

      Seventy-five patients with diagnosed NSCLC have been enrolled into this study. According to the pathological reports, the samples included adenocarcinoma (AC,n=52), adenosquamous carcinoma (ASC,n=5), squamous cell carcinoma (SCC,n=15) and large cell carcinoma (LCC, n=3). The CTLA-4 +49A/G genotype frequencies in NSCLC patients were detected with the following disposition: the frequencies of AA, AG and GG genotype were 53,3% (40/75), 33,3% (25/75) and 13.4% (10/75), respectively. We observed that patients with the GG-genotype of CTLA-4 rs231775 had longer OS compared with patients with an AG or AA genotype.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This study suggests that CTLA-4 rs231775 could potentially be used as a prognostic biomarker.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.